finance.yahoo.com ·
Cytosorbents Corp Ctso Q1 2026
Topic context
This topic has been covered 346763 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedCytoSorbents (CTSO) is a medical device company; its revenue growth is modest and profitability negative. The FDA delay for DrugSorb ATR is a regulatory setback that may slow market access and revenue growth. Foreign exchange losses and geopolitical disruptions in Germany/distributor channels add headwinds. No direct commodity or broad supply-chain impact; the effect is company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $8.9M, +2% YoY
- Direct international business (ex-Germany) +13%
- Germany sales declined; distributor sales flat due to geopolitical disruptions
- Net loss $5.1M from foreign currency impacts
- FDA requested additional data for DrugSorb ATR, delaying de novo submission to late 2026/early 2027
